Biosite(R) Incorporated Adds Two Vice Presidents to Executive Management

Biosite(R) Incorporated Adds Two Vice Presidents to Executive
Management
Leading Bio-Medical Company Adds Prominent Emergency Medicine Physician and
Seasoned Quality Assurance Executive to Team 


SAN DIEGO, June 27  /PRNewswire-FirstCall/ -- Biosite(R) Incorporated
(NASDAQ:BSTE) today announced Norman Paradis, M.D., has been named vice
president medical affairs and S. Elaine Walton has been promoted to vice
president, quality assurance and program management.  Dr. Paradis will provide
medical guidance for clinical trial design, regulatory submissions, new product
prioritization, medical education, and product strategy and positioning. 
Walton, who has more than 20 years of healthcare industry experience, is
responsible for quality assurance, compliance, quality system training,
operational audits and program management.

"With the expansion of our business, it is important for us to broaden
expertise within our management team," said Kim Blickenstaff, Biosite chairman
and chief executive officer.  "Both Norm and Elaine possess experience and
skills that will contribute to Biosite's continued success and market
leadership."

Dr. Paradis has 20 years of clinical, research and administrative experience in
emergency medicine.  Most recently, he was professor of surgery and medicine at
the University of Colorado, and senior medical director of emergency medicine
at University of Colorado Hospital, where he headed a research group with
active programs in real-time diagnostic technology, hemodynamics, hypothermia,
stroke biomarkers, fibrinolytics and emergency cardiopulmonary bypass.

Active in organized medicine, Dr. Paradis has been a member of numerous medical
professional organizations, including the Society for Academic Emergency
Medicine (SAEM), Society of Critical Care Medicine (SCCM), the American College
of Emergency Medicine (ACEP), and the American Academy of Emergency Medicine
(AAEM) among others. Dr. Paradis was one of the founding members of SAEM's
Reperfusion Working Group, and has been active in the American Heart
Association (AHA), serving on the Advanced Cardiac Life Support (ACLS)
Subcommittee for more than 10 years. He is a fellow of the American Board of
Emergency Medicine.

Dr. Paradis is on the editorial boards of The American Journal of Emergency
Medicine, Resuscitation, and the Critical Illness section of the Journal of the
American Medical Association (JAMA).  He has published more than 60 scientific
articles and texts.

Walton joined Biosite in 1997 as the director of program management and was
promoted to senior director in 2004. She created the Company's project
management office, successfully leading multi-disciplinary teams through
processes leading to new product commercialization and ongoing product
improvement.  Walton's expertise contributed to the expansion of Biosite's
product offerings, which consisted of a single drug screening product, the
Triage Drugs of Abuse Panel, in 1997 and today include more than 10 products
addressing a variety of acute diseases and conditions.

Prior to joining Biosite, Walton held the positions of vice president of
quality assurance/compliance/project management and vice president operations
for Nichols Institute Diagnostics (a division of Corning Nichols & Quest
Diagnostics), a biotechnology company that develops, manufactures and markets
medical diagnostic tests and instrumentation.  Prior to that, she obtained
clinical and medical technology experience at SmithKline Clinical Laboratory.

Walton is a Certified Regulatory Affairs Professional, a Certified Quality
Manager and a Certified Project Management Professional. She holds a bachelor's
degree in biology with an emphasis on medical technology from California State
University of Hayward.

About Biosite Incorporated

Biosite Incorporated is a leading bio-medical company commercializing
proteomics discoveries for the advancement of medical diagnosis.  The Company's
products contribute to improvements in medical care by aiding physicians in the
diagnosis of critical diseases and health conditions. Biosite's Triage(R) rapid
diagnostics are used in approximately 50 percent of U.S. hospitals and in over
50 international markets.  Information on Biosite can be found at
http://www.biosite.com/.

Biosite(R), Triage(R) and New Dimensions in Diagnosis(R) are registered
trademarks of Biosite Incorporated. 

DATASOURCE: Biosite Incorporated



CONTACT:  Nadine Padilla, VP, Corporate & Investor Relations of

Biosite Incorporated, [phone], ext. 3187, 



Web site:  http://www.biosite.com/ 



Company News On-Call:  http://www.prnewswire.com/comp/116737.html

Copyright